Gilead Sciences Stock Is Cheap, With Broad Pipeline
Gilead Sciences is a California-based biopharmaceutical company with a $95 billion market cap, known for its treatments in HIV, hepatitis B, hepatitis C, and cancer. In Q2 2023, Gilead Sciences rep...
2 Dirt Cheap High-Yield Dividend Stocks to Buy Right Now
Pfizer is on a roll of important approvals that will eventually fill the gap left by its coronavirus portfolio. Gilead Sciences has a deep lineup and pipeline that are especially concentrated aroun...
Gilead Sciences: A Healthy Buy With Solid Dividend
Gilead Sciences has outperformed the S&P 500 with a 19% total return since my last 'Buy' rating in August last year. Yet, the stock trades at a low PE ratio, especially after trading down over the ...
Gilead's (GILD) Veklury Gets CHMP Nod in Damaged Liver Patients
Gilead's (GILD) Veklury gets a positive CHMP opinion, recommending the use of the drug to treat people with COVID-19 with mild to severe hepatic impairment.
Gilead's (GILD) Trodelvy Combo Shows Promise in NSCLC Study
Gilead's (GILD) breast cancer drug Trodelvy, in combination with Keytruda, shows positive data in a phase II lung cancer study.
3 Dividend Stocks for September 2023
#Morningstar #PfizerStock #DividendStocks Dividend investors: Put these cheap stocks on your buy list. 00:00 Introduction 00:28 Pfizer PFE 01:03 Medtronic MDT 01:34 Gilead Sciences GILD Susan Dziu...
Pfizer Vs. Gilead Sciences: COVID-19 Battle Of Pharma Titans
Wall Street underestimates the prospects of Pfizer and Gilead Sciences, given their significant role in developing vaccines and medicines against COVID-19. Gilead Sciences' revenue has remained sta...
Bank of America says buy Gilead
The "Halftime Report" traders debate the biggest analyst calls of the day.
Gilead Stock Looks Underappreciated and Oversold, Say BofA Analysts
BofA upgraded shares of biotech Gilead to Buy from Neutral, and lifted the target price to $95 from $88.
Gilead Sciences, Inc. (GILD) Wells Fargo Healthcare Conference - (Transcript)
Gilead Sciences, Inc. (NASDAQ:GILD ) Wells Fargo Healthcare Conference September 6, 2023 11:00 AM ET Company Participants Andrew Dickinson - Chief Financial Officer Conference Call Participants Moh...
Arcus Biosciences: Huge Cash, Gilead Deal, Not A Lot Of Data
Arcus Biosciences, Inc. stock has dropped 40% since its high in 2022, making it an attractive investment opportunity. The company has major deals with Gilead, Roche/Genentech, and AstraZeneca, and ...
Gilead (GILD) Gets FDA Nod for Veklury for Hepatic Impairment
Gilead's (GILD) anti-viral treatment Veklury gets FDA approval for the treatment of COVID-19 in patients with mild, moderate or severe hepatic impairment.
GILD Stock Alert: FDA Approves Gilead Sciences' Veklury Covid-19 Treatment
Gilead Sciences (NASDAQ: GILD ) stock is on the move Thursday following FDA approval for its Veklury Covid-19 treatment. This saw the FDA approve the company's supplemental new drug application (sN...
Gilead, Arcus, iTeos, other biopharmas get boost from accidental disclosure of Roche lung cancer trial data
Shares of biopharmaceutical companies developing anti-TIGIT cancer therapies, including Gilead Sciences Inc. GILD, +0.54%, Arcus Biosciences Inc. RCUS, -0.84% and iTeos Therapeutics Inc. ITOS, +2.8...
Gilead's (GILD) Leukemia Study Progress Put on Clinical Hold
Gilead (GILD) faces a setback as the FDA puts a partial clinical hold on enrolling new patients in studies evaluating magrolimab for treating AML in the United States.
Related Companies